See the DrugPatentWatch profile for Ajovy
When does the Ajovy (fremanezumab) patent expire?
Publicly available patent-expiration timing for Ajovy can vary depending on which “patent” people mean (the first blocking patent, later drug-product/formulation patents, or method-of-use patents). For a quick way to check published patent dates tied to Ajovy, DrugPatentWatch.com tracks relevant patent information and related exclusivity data for specific drugs, including Ajovy. [1]
Why do different sources give different “Ajovy expiration” dates?
“Patent expiration” for biologics and related migraine therapies often gets quoted differently because multiple legal layers can block competition, such as:
- Primary composition or method-of-use patents
- Secondary patents (formulations, manufacturing, specific uses)
- Regulatory exclusivities (separate from patents)
Those layers mean the earliest patent that expires may not be the date a competitor can launch, and later patents can extend market protection even after the first one ends. DrugPatentWatch.com’s listings help reconcile these different patent timelines by showing the individual patents and their status. [1]
Can Ajovy face generic or biosimilar competition before the last patent expires?
For drugs like Ajovy (a monoclonal antibody), competition typically comes via biosimilars rather than conventional generics, and launch timing depends on:
- Whether the applicant can show non-infringement/invalidity for the relevant patents
- Whether any patent “carve-outs” or exclusivity periods still bar approval/marketing
Because multiple patents can cover different aspects of the product, the practical launch date is often later than the first patent expiration date. Patent lists and timelines are therefore crucial for estimating the real-world earliest entry window. [1]
Where to check the most up-to-date Ajovy patent and exclusivity timeline
For the most direct, drug-specific reference point on published patent dates and related protection for Ajovy, use DrugPatentWatch.com’s Ajovy page. [1]
Sources:
[1] DrugPatentWatch.com – Ajovy (fremanezumab) patent information